全文获取类型
收费全文 | 950篇 |
免费 | 126篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 37篇 |
妇产科学 | 12篇 |
基础医学 | 102篇 |
口腔科学 | 20篇 |
临床医学 | 111篇 |
内科学 | 228篇 |
皮肤病学 | 3篇 |
神经病学 | 42篇 |
特种医学 | 60篇 |
外科学 | 105篇 |
综合类 | 30篇 |
预防医学 | 113篇 |
眼科学 | 4篇 |
药学 | 73篇 |
中国医学 | 3篇 |
肿瘤学 | 159篇 |
出版年
2021年 | 7篇 |
2020年 | 7篇 |
2019年 | 16篇 |
2018年 | 18篇 |
2017年 | 15篇 |
2016年 | 10篇 |
2015年 | 16篇 |
2014年 | 27篇 |
2013年 | 25篇 |
2012年 | 33篇 |
2011年 | 43篇 |
2010年 | 38篇 |
2009年 | 39篇 |
2008年 | 42篇 |
2007年 | 50篇 |
2006年 | 39篇 |
2005年 | 39篇 |
2004年 | 18篇 |
2003年 | 27篇 |
2002年 | 21篇 |
2001年 | 16篇 |
2000年 | 23篇 |
1999年 | 31篇 |
1998年 | 21篇 |
1997年 | 26篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 26篇 |
1993年 | 25篇 |
1992年 | 25篇 |
1991年 | 24篇 |
1990年 | 20篇 |
1989年 | 27篇 |
1988年 | 22篇 |
1987年 | 21篇 |
1986年 | 22篇 |
1985年 | 20篇 |
1983年 | 10篇 |
1982年 | 15篇 |
1981年 | 14篇 |
1980年 | 13篇 |
1979年 | 15篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 14篇 |
1974年 | 15篇 |
1973年 | 10篇 |
1972年 | 9篇 |
1971年 | 10篇 |
1970年 | 7篇 |
排序方式: 共有1107条查询结果,搜索用时 15 毫秒
1.
Neuroimaging in Pineal Tumors 总被引:4,自引:0,他引:4
F Reis MD AV Faria MD PhD VA Zanardi MD PhD JR Menezes MD F Cendes MD PhD LS Queiroz MD PhD 《Journal of neuroimaging》2006,16(1):52-58
BACKGROUND AND PURPOSE: The authors report radiological findings in 11 tumors in the pineal region, which were histologically diagnosed as germinomas, pineocytomas pineoblastomas, ependymomas, teratomas, and astrocytomas. METHODS: Computed tomography (CT) was performed in seven patients and magnetic resonance imaging (MRI) was performed in all patients. RESULTS: CT showed a solid or solid/cystic mass with variable contrast enhancement. MRI showed a heterogeneous mass, with hypointense signal on T1 and iso/hyperintense signal on T2-weighted images (WI) and gadolinium enhancement. Extension to adjacent structures occurred in five patients and spread through the cerebral spinal fluid (CSF) in two. CONCLUSIONS: Pineal region tumors have no pathognomonic imaging pattern. MRI and CT are complementary in diagnosis and are important to determine localization, extension, and meningeal spread. 相似文献
2.
Identification of the protein encoded by the human diffuse B-cell lymphoma (dbl) oncogene. 总被引:1,自引:0,他引:1 下载免费PDF全文
S K Srivastava R H Wheelock S A Aaronson A Eva 《Proceedings of the National Academy of Sciences of the United States of America》1986,83(23):8868-8872
The dbl oncogene was initially isolated from a human diffuse B-cell lymphoma. Antisera from mice bearing tumors induced by this oncogene specifically detected a protein of about 66 kDa (p66) in dbl transformants. dbl cDNA-selected poly(A)+ RNA isolated from a transfectant clone expressing p66 directed the in vitro synthesis of this protein, establishing that it is encoded by dbl. Subcellular localization studies revealed that p66 is a cytoplasmic protein distributed between cytosol and crude membrane fractions. Moreover, p66 was shown to be a phosphoprotein, with phosphorylation specific to serine residues. Our characterization of the dbl-encoded protein appears to distinguish this transforming gene product from those of other known oncogenes. 相似文献
3.
Devang N Patel Francis D Pagani Todd M Koelling David B Dyke Ragavendra R Baliga Robert J Cody Kathleen D Lake Keith D Aaronson 《The Journal of heart and lung transplantation》2002,21(2):204-210
BACKGROUND: Pravastatin and simvastatin prolong survival and reduce transplant-related coronary vasculopathy, although low-density lipoprotein (LDL) lowering with these agents is only modest. The objective of this study was to assess the safety of moderate dose atorvastatin and its efficacy when prior treatment with another statin had failed to lower LDL to < 100 mg/dl. METHODS: Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure. Changes in lipid parameters, and prednisone and cyclosporine doses were determined. RESULTS: Safety: 48 patients received atorvastatin for 24,240 person-days at a mean dose exposure of 21 +/- 10 mg. Rhabdomyolysis, myositis, myalgias, and hepatotoxicity occurred in 0, 2, 2, and 0 patients, respectively. All events occurred at the 10-mg dose, within the first 3 months, and were rapidly reversible with atorvastatin discontinuation. Efficacy: Thirty-four patients evaluable for efficacy analyses had a pre-atorvastatin LDL of 145 +/- 38 mg/dl on the following statins: pravastatin (n = 30, 40 +/- 0mg), fluvastatin (n = 3, 33 +/- 12 mg), simvastatin (n = 1, 40 mg). After atorvastatin (21 +/- 9 mg/day) for 133 +/- 67 days, LDL was reduced to 97 +/- 24 mg/dl (relative reduction 31 +/- 20%, p < 0.0001). At the end of the observation period (418 +/- 229 days, atorvastatin final dose 24 +/- 14 mg/day), LDL was further decreased to 88 +/- 23 mg (relative reduction 37 +/- 17%, p < 0.0001). CONCLUSION: Atorvastatin, when used at moderate doses and with close biochemical and clinical monitoring, appears to be safe and is effective in aggressively lowering LDL in heart transplant recipients when treatment with other statins has failed to achieve LDL goals. 相似文献
4.
Todd M. Koelling MD FACC Susan Joseph MD Keith D. Aaronson MD 《The Journal of heart and lung transplantation》2004,23(12):232-1422
BACKGROUND: The Heart Failure Survival Score (HFSS) has been previously shown to effectively risk-stratify patients under evaluation for heart transplantation. However, this model was developed before broad use of beta blockade. We hypothesized that the prognostic tool would retain its ability to risk stratify patients treated with beta-blockers. METHODS: We collected clinical data on 524 consecutive patients referred for heart transplantation from 1994 to 2001. Kaplan-Meier survival analysis and multivariable Cox regression analysis were performed with events defined as death, left ventricular assist device placement, or United Network of Organ Sharing 1 heart transplantation. RESULTS: Kaplan-Meier analysis of the patient population revealed effective discrimination by the survival score both for beta-blocker treated and untreated patients (both p <0.0001). Two-year event-free survival was 94% +/- 2% and 84% +/- 4% for beta-blocker and no beta-blocker patients in the low-risk HFSS strata. Cox proportional hazard modeling showed that HFSS strata (medium risk: HR 2.65, 95% CI 1.75-4.02, p <0.001; high risk: HR 5.51, 95% CI 3.64-8.33, p <0.001) and beta-blocker treatment (HR 0.45, 95% CI 0.31-0.64, p <0.001) were significant predictors of event-free survival. Receiver operating curves (area under the curve) for HFSS strata used to predict 2-year events were similar for beta-blocker treated (0.78 +/- 0.04) and untreated (0.80 +/- 0.03) patients. CONCLUSIONS: The HFSS provides effective risk stratification with or without beta-blocker therapy. Consideration of beta-blocker therapy with survival score strata improves outcome prediction in patients evaluated for heart transplantation. 相似文献
5.
6.
7.
Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes 总被引:6,自引:0,他引:6
Insulin-sensitizing thiazolidinediones such as troglitazone and pioglitazone have been shown to lower blood pressure in vivo and cause vasorelaxation in vitro. Rosiglitazone (BRL 49653) is a novel thiazolidinedione which has been reported not to cause vasoleraxation. We therefore compared the effects of troglitazone and rosiglitazone on Ca2+ and K+ currents in rat aorta and pulmonary artery smooth muscle cells. Currents were recorded with the conventional whole cell patch clamp technique. Both drugs reduced the voltage-gated (L-type) Ca2+ current in rat aorta cells, with half-maximal current inhibition by troglitazone and rosiglitazone at 2 and 10 microM, respectively. Troglitazone, 2 microM and rosiglitazone, 20 microM caused a similar hyperpolarizing shift of 12 mV in the potential-dependence of Ca2+ current availability. Troglitazone (20 microM) produced a marked block of the tetraethylammonium- and paxilline-sensitive Ca2+ activated K+ current, while rosiglitazone (20 microM and 60 microM) slightly enhanced this current. Rat pulmonary artery smooth muscle cells have a prominent delayed rectifier K+ current. Troglitazone produced a potent block of this current (half-maximal inhibition at <1 microM), while rosiglitazone caused a smaller inhibition at 10 and 60 microM. These results show that troglitazone has relatively potent blocking effects on a wide variety of ion currents in vascular smooth muscle cells. Rosiglitazone exerts less potent, but similar effects on the Ca2+ current and delayed rectifier K+ current, but it enhances the Ca2+ activated K+ current. reserved. 相似文献
8.
Thiazolidinediones are insulin-sensitising agents effective in controlling type II diabetes. These compounds also cause vasodilation. We evaluated the effects of the thiazolidinediones troglitazone and rosiglitazone on the glibenclamide-sensitive K(+) current in freshly isolated rat aorta myocytes. Troglitazone inhibited this current in a concentration-dependent manner (IC(50) approximately 1 microM). Rosiglitazone had a similar, but much less potent (IC(50) approximately 20 microM) action. Block of the glibenclamide-sensitive K(+) channels, in particular by troglitazone, may potentially affect the response of arteries to hypoxia and to certain endogenous and exogenous vasodilators. 相似文献
9.
Mechanism of activation of an N-ras oncogene of SW-1271 human lung carcinoma cells. 总被引:15,自引:8,他引:7 下载免费PDF全文
Y Yuasa R A Gol A Chang I M Chiu E P Reddy S R Tronick S A Aaronson 《Proceedings of the National Academy of Sciences of the United States of America》1984,81(12):3670-3674
An N-ras-related transforming gene was detected in the human lung carcinoma cell line SW-1271 and molecularly cloned. The lesion responsible for its acquisition of transforming activity was localized to a single nucleotide transition from A to G in codon 61 of the predicted protein. This lesion in the second exon results in the substitution of arginine for glutamine at this position. These findings, together with previous studies, indicate that the activation of ras oncogenes in human tumors is most commonly due to point mutations at one of two major "hot spots" in the ras coding sequence. 相似文献
10.